Adaptive Biotechnologies (ADPT) Asset Writedowns and Impairment (2025 - 2026)
Adaptive Biotechnologies (ADPT) posted Asset Writedowns and Impairment of $347000.0 for Q1 2026, down 38.37% sequentially from $563000.0 in Q4 2025.
Adaptive Biotechnologies (ADPT) Asset Writedowns and Impairment (2025 - 2026) Analysis & Trends
Adaptive Biotechnologies has reported Asset Writedowns and Impairment for 2 years, with the latest figure at $347000.0 in Q1 2026.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $347000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $910000.0 (changed N/A YoY) and the FY2025 annual result came in at $563000.0, down 92.19% from the prior year.
- Asset Writedowns and Impairment slipped to $347000.0 in Q1 2026 per ADPT's latest filing, from $563000.0 in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $563000.0 in Q4 2025 and troughed at $347000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn |
| 10 | Adaptive Biotechnologies | 4.23 Bn | 3.89 Bn | 51.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 347,000.00 |
| Mar 31, 2026 | 347,000.00 |
| Dec 31, 2025 | 563,000.00 |
| Dec 31, 2025 | 563,000.00 |
| Jun 30, 2025 | 55,000.00 |
| Jun 30, 2025 | 55,000.00 |
| Mar 31, 2025 | -101,000.00 |
| Mar 31, 2025 | -101,000.00 |